Biotech | May 26, 2026
Genethon and Ampersand team up to engineer next-gen gene therapy vectors with precision
AAV vectors are widely used in gene therapy for their strong therapeutic potential
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
